CHRS - Earnings announcements

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 11, 2026, starting at 5:00 p.m. Eastern Standard Time To access the conference call, please pre-register through the followin

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights. "In Q3 2025, we gained significant momentum on our strategy to develop innovative oncology therapies that substantially increase patient sur

REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, November 6, 2025, starting at 5:00 p.m. Eastern Standard Time To access the conference call, please pre-register thr

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent business highlights. "Coherus Oncology is dedicated to significantly extending survival for people with cancer," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "We are execu

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ((Coherus, Coherus Oncology or the Company, NASDAQ:CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, August 7, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 12, 2025 (GLOBE N

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference call, please pre-register through

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced data from its ongoing Phase 1

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.me

- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody - - Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026 - - Coherus management to host investor conference call today, Tuesday, December 3, 2024, at 8:00 a.m. Eastern Time - REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, November 6, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the f

 – Net revenue of $77.1 million in Q1 2024 –  – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights:  RECENT BUSINESS HIGHLIGHTS UDENYCA® RESULTS and ONBODY™ LAUNCH UPDATE UDENYCA net product sales were $42.7 million in Q1 2024, an increase of 18% compared to $36.2 million

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, May 9, 2024, starting at 5:00 p.m. Eastern Daylight Time To access the conference call:Dial: (800) 715-9871 (toll-free USA

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Wednesday, March 13, 2024, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-re

– Transaction aligns to Coherus' strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for upfront, all-cash consideration of $170 million plus an additional amount for CIMERLI product inventory and subject to customary working capital adjustments at the closing date. This divestiture includes Coherus' CIMERLI biologics license application, ophthal

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, November 6, 2023, starting at 5:00 p.m. Eastern TimeTo access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/registe

–  LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status – –  Conference today at 4:30 p.m. Eastern Daylight Time – REDWOOD CITY, Calif. and SHANGHAI, China, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), and  Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that the U.S. Food and Drug Administration (FDA) approved LOQTORZI™ (toripalimab-tpzi) in combination with cisplatin and gemcitabine f

REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Wednesday, August 2nd, 2023, starting at 5:00 p.m. Eastern TimeTo access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call:  https://register.vevent.com/register

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affir

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs–       – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and

– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of toripalimab manufacturing site scheduled for May 2023 –– Toripalimab launch anticipated in Q3 2023, if approved –– YUSIMRY™ ready for planned July 2023 launch –– FDA review of UDENYCA® OBI BLA supplement progressing; launch anticipated in 2023, if approved –– Net product revenue of $32.4 million in the first quarter 2023 –– Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", "the Company", NASDAQ:CHRS), today r

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call. Conference Call InformationWhen: Monday, May 8th, 2023, starting at 5:00 p.m. Eastern TimeTo access the conference call, please pre-register through the following link to r

– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 –– FDA is planning the toripalimab manufacturing site inspection in Q2 2023 –– UDENYCA® autoinjector approved by FDA; UDENYCA® on-body injector under review by FDA –– Planning underway for potential 2023 commercial launches of toripalimab, YUSIMRY™, UDENYCA® AI and UDENYCA® OBI –– Conference call today at 5 p.m. ET – REDWOOD CITY, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2022 and recent business highlights: RECENT BUSINESS HIGHLIG

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call. Conference Call InformationWhen: Monday, March 6th, 2023, starting at 5:00 p.m. Eastern TimeTo access the conference call, please pre-regis

– UDENYCA® net sales of $45.4 million in the third quarter 2022 –– CIMERLI™ launched in the United States on October 3rd –– Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and UDENYCA® OBI –– Conference call today at 5 p.m. ET – REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights: RECENT BUSINESS HIGHLIGHTS CIMERLI™ (ranibizumab-eqrn), was approved in August 2022 by the U.S. Food and Drug Administration (FDA) as a biosimilar product interchangeable with Lucentis® (ra

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022. Starting at 5:00 p.m. Eastern Time on November 8, 2022, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. The press release with the third quarter 2022 financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call. A replay of the webcast will be available on http://investors.coherus.com following the

– Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway for planned July 2023 launch of YUSIMRY™ –– UDENYCA® delivers 2nd quarter 2022 net sales of $60.1 million –– Conference call today at 5 p.m. ET – REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS), today reported financial results for the quarter ended June 30, 2022 and recent business highlights: RECENT BUSINESS HIGHLIGHTS The U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (rani

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. After releasing second quarter 2022 financial results, the Company will post them on the Coherus website at https://investors.coherus.com. Conference Call InformationWhen: Thursday, August 4th, 2022, starting at 5 p.m. ETDial-in: (800) 715-9871 (Toll-Free U.S. and Canada) or (646) 307-1963 (Internati

– CIMERLI™ BLA review progressing toward August 2022 action date –– Toripalimab BLA resubmission expected by mid-summer –– UDENYCA® delivers 1st quarter 2022 net sales of $60.1 million –– 2022 R&D and SG&A expense guidance reduced by $20 million –– Conference call today at 4:30 p.m. ET – REDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reported financial results for the quarter ended March 31, 2022 and recent business highlights: RECENT BUSINESS HIGHLIGHTS After receiving a complete response letter ("CRL") for the Biologics License Application ("BLA") for toripalimab, Coherus and partner Shanghai Junshi B

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (NASDAQ:CHRS), please note in the Conference Call Information, the start time should be 4:30 p.m. ET, not 5 p.m. ET as previously stated. The corrected release follows: Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022. Starting at 4:30 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. After rel

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022. Starting at 4:30 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. After releasing first quarter 2022 financial results, the Company will post them on the Coherus website at https://investors.coherus.com. Conference Call InformationWhen: Thursday, May 5th, 2022, starting at 5 p.m. ETDial-in: (844) 452-6826 (Toll-Free U.S. and

– YUSIMRY™ (adalimumab-aqvh), Coherus' second product, approved by FDA on December 17, 2021 –– BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI™ (ranibizumab-ranq) –– New FDA filings expected in 2022 for UDENYCA® on-body injector and additional toripalimab indications –– UDENYCA® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 –– Conference call and webcast today at 5:00 p.m. ET – REDWOOD CITY, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reported financial results for the quarter and full year ended December 31, 2021 and highlighted recent achievement of important milestones to

REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. After releasing fourth quarter and full year 2021 financial results, the Company will post them on the Coherus website at https://investors.coherus.com. Conference Call InformationWhen: Thursday, Feb. 17, 2022, starting at 5 p.m. ETDial-in: (844) 452-6826 (Toll-Free U.S. and Canada) or

– Key milestones achieved driving near-term commercial product portfolio expansion – – Three BLAs now under FDA review: PD-1 inhibitor toripalimab, biosimilar Lucentis®, biosimilar Humira® – – Multiple additional applications to FDA expected in 2022 – – UDENYCA® delivers 3rd quarter 2021 net sales of $83 million – – Conference call today at 5:00 p.m. ET – REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reported financial results for the quarter ended September 30, 2021 and highlighted recent achievement of key milestones toward potential near-term expansion of the commercial product portfolio: ACHIEVE

REDWOOD CITY, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. After releasing third quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com. Conference Call Information When: Monday, Nov. 8, 2021, starting at 5 p.m. ETDial -in: (844) 452-6826 (Toll-Free U.S. and Canada) or (765) 507-2587 (International)Confer

–1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA — – CHS-201 (Lucentis® biosimilar) BLA submitted to FDA – –CHS-1420 (Humira® biosimilar) BLA review progressing with December target action date – – Second quarter 2021 UDENYCA® net sales of $88 million – – Conference call today at 5:00 p.m. ET – REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reported financial results for the quarter ended June 30, 2021. The Company also provided a progress update on its PD-1 blocking antibody, toripalimab, its lead immuno-oncology candidate f

REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. After releasing second quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com. Conference Call Information When: Thursday, August 5, 2021 starting at 5:00 p.m. ET Dial-in: (844) 452-6826 (Toll-Free U.S. and Canada) or (765) 507-2587 (Internationa